Peter K. Kaiser
Corporate Officer/Principal chez OCULAR THERAPEUTIX, INC.
Postes actifs de Peter K. Kaiser
Sociétés | Poste | Début | Fin |
---|---|---|---|
OCULAR THERAPEUTIX, INC. | Corporate Officer/Principal | 22/02/2024 | - |
Cole Eye Institute | Corporate Officer/Principal | - | - |
The Retina Society | Corporate Officer/Principal | - | - |
Macula Society | Corporate Officer/Principal | - | - |
American Ophthalmological Society
American Ophthalmological Society Miscellaneous Commercial ServicesCommercial Services The American Ophthalmological Society is an organization that aims to promote excellence in patient care, education, and research in the field of ophthalmology. The society is based in San Francisco, CA, and was founded in 1864 by Edward Delafield, Daniel Bennett St. John Roosa, and Henry Noyes. The private company addresses essential issues in medicine and advance the art and science of ophthalmology. The society holds annual meetings every third week of May each year, and they offer travel grants to non-members who wish to attend. Membership nominations are accepted until April 30th each year. | Corporate Officer/Principal | - | - |
Historique de carrière de Peter K. Kaiser
Anciens postes connus de Peter K. Kaiser
Sociétés | Poste | Début | Fin |
---|---|---|---|
SKS Ocular LLC
SKS Ocular LLC BiotechnologyHealth Technology SKS Ocular, LLC is a private ophthalmology company incubator that uses state-of-the-art research and development technologies to discover and advance novel therapeutics through preclinical or clinical proof of concept. | Directeur Technique/Scientifique/R&D | - | - |
Fondateur | - | - | |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Corporate Officer/Principal | 02/06/2014 | - |
Formation de Peter K. Kaiser
Harvard Medical School | Doctorate Degree |
Harvard College | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Opérationnelle
Corporate Officer/Principal | 6 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
OCULAR THERAPEUTIX, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Macula Society | |
American Ophthalmological Society
American Ophthalmological Society Miscellaneous Commercial ServicesCommercial Services The American Ophthalmological Society is an organization that aims to promote excellence in patient care, education, and research in the field of ophthalmology. The society is based in San Francisco, CA, and was founded in 1864 by Edward Delafield, Daniel Bennett St. John Roosa, and Henry Noyes. The private company addresses essential issues in medicine and advance the art and science of ophthalmology. The society holds annual meetings every third week of May each year, and they offer travel grants to non-members who wish to attend. Membership nominations are accepted until April 30th each year. | Commercial Services |
The Retina Society | |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Health Technology |
Cole Eye Institute | |
SKS Ocular LLC
SKS Ocular LLC BiotechnologyHealth Technology SKS Ocular, LLC is a private ophthalmology company incubator that uses state-of-the-art research and development technologies to discover and advance novel therapeutics through preclinical or clinical proof of concept. | Health Technology |
- Bourse
- Insiders
- Peter K. Kaiser
- Expérience